A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation

NCT07231068 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

153

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Dositinib mesylate tablets

Sponsor

Henan Genuine Biotech Co., Ltd.